ReviewCardio-oncology (London, England)2023
Anthracycline cardiotoxicity: current methods of diagnosis and possible role of
Review in Cardio-oncology (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Serial cardiac MR assessment and histopathological evaluation of doxorubicin-induced cardiomyopathy in a miniature swine model.BMC cardiovascular disorders · 2026Article
- Association between Cardiac Metabolic Patterns in Oncological PET/CT and Cardiovascular Risk Factors. Contribution to the Early Investigation of Cardiotoxicity.Arquivos brasileiros de cardiologia · 2026Article
- The Imaging Value ofMolecular imaging and biology · 2025Article
- Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment.Life (Basel, Switzerland) · 2025Review
- Cardioprotection strategies for anthracycline cardiotoxicity.Basic research in cardiology · 2025Review
- Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study.Journal of intensive medicine · 2025Article
- Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.Circulation. Cardiovascular quality and outcomes · 2025Article
- Progression of Myocardial 18F-FDG Uptake in a Patient with Cardiotoxicity.Arquivos brasileiros de cardiologia · 2024Article
- Physiological myocardialAsia Oceania journal of nuclear medicine & biology · 2024Article
- Article
- Multimodality Cardiovascular Imaging of Cardiotoxicity Due to Cancer Therapy.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in chemotherapy, the drugs used in cancer treatment remain rather harmful to the cardiovascular system, causing structural and functional cardiotoxic changes. Positron-emission tomography associated with computed tomography (PET/CT) has emerged like a promising technique in the early diagnosis of these adverse drug effects as the myocardial tissue uptake of fluorodeoxyglucose labeled with fluorine-18 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.